Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Individualized Venetoclax Dosing Based on PK/PD in Pediatric Refractory/Relapsed Acute Leukemia
ChiCTR2200057796Phase 4Recruiting
- Sponsor
- Beijing Children's Hospital
- Start
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of venetoclax in leukemia, sponsored by Beijing Children's Hospital. Primary endpoints: Plasma drug concentration of venetoclax and Hematologic complete remission. Started Mar 2022; status: recruiting.
02
Drugs
venetoclax
03
Conditions
leukemia
Beyond the preview
Go deeper on ChiCTR2200057796.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200057796.